Amgen Appoints Esteban Santos Executive Vice President, Operations





Amgen announced the appointment of Esteban Santos as executive vice president, Operations, effective July 25, 2016, reporting to Robert A. Bradway, chairman and chief executive officer. Santos will be responsible for Amgen's Operations organization which encompasses manufacturing, process development, quality, engineering and global supply chain. He will succeedMadhavan (Madhu) Balachandran, 65, who is retiring at the end of the year.
Santos, 48, has been senior vice president, Manufacturing with responsibilities for worldwide product supply since 2013. He joined Amgen in 2007 and previously held various leadership roles, including vice president, Drug Product; vice president, Site Operations; vice president, Manufacturing; and vice president, Engineering.
Before joining Amgen, Santos was site general manager for the Johnson & Johnson (J&J) Cordis operation in Puerto Rico. Prior to J&J, Santos held several management positions in General Electric's industrial and transportation businesses in Puerto Rico, Connecticut, and Pennsylvania. Santos holds a bachelor of science degree in electrical engineering from the University of Puerto Rico – Mayagüez and a master of science in management from theRensselaer Polytechnic Institute, Hartford, Connecticut.
Bradway said, "Esteban is a talented leader with a proven track record. I'm confident that Esteban and our Operations team will maintain our track record of industry-leading performance in serving 'every patient, every time' as we expand globally, launch new products and introduce our next-generation of biomanufacturing technologies."
Succeeding Santos as senior vice president, Manufacturing will be Robert Maroney, who is currently vice president, Site Operations at Amgen Manufacturing, Ltd. in Juncos, Puerto Rico.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.For more information, visit www.amgen.com    
CONTACT:
Amgen, Thousand Oaks
 
Kristen Davis,
805-447-3008 (media)
 
Arvind Sood,
805-447-1060 (investors)